SCHEMBL5010424

SCHEMBL5010424

CCCCN(C(=O)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1)C1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.42
HTT P42858 2/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.36
LMNA P02545 1/20 0.36
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
UBE2M P61081 1/20 0.34
DCUN1D1 Q96GG9 1/20 0.34
PYGL P06737 1/20 0.33
INSR P06213 1/20 0.33
IGF1R P08069 1/20 0.33
ALK Q9UM73 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5009754 0.92 NPC1 (0.42) HTTRECQLSMN1; SMN2HPGDCYP2C19
SCHEMBL5008205 0.91 HTT (0.41) ENPP2HTTRECQLSMN1; SMN2HPGD
SCHEMBL5009775 0.90 HTT (0.40) ENPP2HTTRECQLSMN1; SMN2HPGD
SCHEMBL5013415 0.90 HTT (0.39) ENPP2HTTRECQLSMN1; SMN2HPGD
SCHEMBL14587650 0.90 ENPP2 (0.42) ENPP2HTTRECQLSMN1; SMN2HPGD
SCHEMBL5010461 0.89 HTT (0.39) ENPP2HTTRECQLSMN1; SMN2HPGD
SCHEMBL14587654 0.88 ALDH1A1 (0.47) HTTRECQLSMN1; SMN2HPGDLMNA
SCHEMBL5013637 0.88 ALDH1A1 (0.39) HTTRECQLSMN1; SMN2HPGDLMNA
SCHEMBL5008467 0.87 HTT (0.37) ENPP2HTTRECQLLMNACYP2C19
SCHEMBL5010796 0.86 NPC1 (0.43) ENPP2HTTRECQLSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL ENPP2 1877/4885HTT 4237/4885RECQL 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.